- Home
- ASBP vs CODX Comparison
ASBP vs CODX Comparison
Compare ASBP & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASBP
- CODX
- Stock Information
- Founded
- ASBP 2021
- CODX 2013
- Country
- ASBP United States
- CODX United States
- Employees
- ASBP N/A
- CODX N/A
- Industry
- ASBP Biotechnology: Pharmaceutical Preparations
- CODX Medical/Dental Instruments
- Sector
- ASBP Health Care
- CODX Health Care
- Exchange
- ASBP Nasdaq
- CODX Nasdaq
- Market Cap
- ASBP 11.9M
- CODX 9.8M
- IPO Year
- ASBP N/A
- CODX 2017
- Fundamental
- Price
- ASBP $0.28
- CODX $0.28
- Analyst Decision
- ASBP
- CODX Buy
- Analyst Count
- ASBP 0
- CODX 2
- Target Price
- ASBP N/A
- CODX $5.50
- AVG Volume (30 Days)
- ASBP 4.2M
- CODX 462.7K
- Earning Date
- ASBP 08-24-2025
- CODX 08-07-2025
- Dividend Yield
- ASBP N/A
- CODX N/A
- EPS Growth
- ASBP N/A
- CODX N/A
- EPS
- ASBP N/A
- CODX N/A
- Revenue
- ASBP N/A
- CODX $3,497,583.00
- Revenue This Year
- ASBP N/A
- CODX N/A
- Revenue Next Year
- ASBP N/A
- CODX $42.11
- P/E Ratio
- ASBP N/A
- CODX N/A
- Revenue Growth
- ASBP N/A
- CODX N/A
- 52 Week Low
- ASBP $0.22
- CODX $0.23
- 52 Week High
- ASBP $15.80
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- ASBP N/A
- CODX 43.19
- Support Level
- ASBP N/A
- CODX $0.26
- Resistance Level
- ASBP N/A
- CODX $0.29
- Average True Range (ATR)
- ASBP 0.00
- CODX 0.02
- MACD
- ASBP 0.00
- CODX 0.00
- Stochastic Oscillator
- ASBP 0.00
- CODX 26.83
About ASBP Aspire Biopharma Holdings Inc. Common Stock
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.